RC
RA Capital Nexus Fund II, L.P.
DELAYED 1 MONTH
Director
Acrivon Therapeutics, Inc.
Acumen Pharmaceuticals, Inc.
Climb Bio, Inc.
Hemab Therapeutics Holdings, Inc.
Filings
4
Companies
4
Latest
Jun 5, 2026
Transactions
Signal
Ticker / Company
Insider
Transaction
Value
Filed
—
Hemab Therapeutics Holdings, Inc.
RA Capital Nexus Fund II, L.P.
Director
Purchase
$1.7M
68,018 sh
May 6 11:16 PM
May 6, 2026
—
Hemab Therapeutics Holdings, Inc.
RA Capital Nexus Fund II, L.P.
Director
Purchase
$2.4M
97,411 sh
May 6 11:16 PM
May 5, 2026
—
Hemab Therapeutics Holdings, Inc.
RA Capital Nexus Fund II, L.P.
Director
Purchase
$48.1M
2,675,000 sh
May 6 11:16 PM
May 4, 2026